St. Jude Clinical Trials
HALGG: Hippocampal-Avoidance Using Proton Therapy in Children with Brain Tumors
Diseases Treated:
Eligibility:
- At least 6 years old and younger than 22
- Diagnosis of low-grade glioma
MEMCRT: Memantine to Prevent Thinking Problems in Children Receiving Radiation for Certain Brain Tumors
Diseases Treated:
Eligibility:
- Between 6 and 21 years old
- Diagnosis of localized low-grade glioma, craniopharyngioma, ependymoma, meningioma or germ cell tumor
- Initiating focal cranial radiation therapy (photon or proton)
- Able to swallow pills
- Participant and parent/legal guardian speak, read and understand English
- Normal ECG and laboratory tests
- Adequate vision and hearing
RT3CR: Proton Therapy for Pediatric Craniopharyngioma
Diseases Treated:
Eligibility:
- 21 years old or younger
- Diagnosis of craniopharyngioma
SJ901: Study of Mirdametinib as a Treatment for Children, Adolescents and Young Adults with Low-Grade Glioma
Diseases Treated:
Eligibility:
At least 2 years old and younger than 25 years old
Diagnosis of progressive or relapsed low-grade glioma
SJiMB21: Risk-Based Medulloblastoma Treatment for Infants and Young Children
Diseases Treated:
Eligibility:
- All patients with newly diagnosed medulloblastoma between birth and 3 years old
- A select group of low-risk patients with newly diagnosed medulloblastoma between 3 and 5 years old
- No previous radiotherapy, chemotherapy, or other treatment for the brain tumor other than corticosteroid therapy and surgery
Eligibility Exclusions:
- Other medical disorders, such as serious infections or significant heart, lung, liver, psychiatric, or other organ problems that could make it hard to cope with the trial treatment or would interfere with the study procedure
SJMB12: A Clinical and Molecular Risk-Directed Therapy for Newly Diagnosed Medulloblastoma/PNET
Diseases Treated:
Medulloblastoma (includes all variants of medulloblastoma and posterior fossa PNET)
Eligibility:
- Diagnosis of newly medulloblastoma
- At least 3 years old and younger than 22 years old (Strata W, S or N) OR
- At least 22 years old and younger than 40 years old AND has SHH medulloblastoma (Stratum S)
- Has not received previous treatment with radiation therapy or chemotherapy
- Must start treatment within 36 days of surgery to remove the tumor
Collaborative Clinical Trials
LOXORET: Phase I/II Study of LOXO-292 (Selpercatinib) in Patients with Advanced RET-Altered Solid Tumors or Brain Tumors
Diseases Treated:
Solid tumors, Brain tumors
Eligibility:
- 6 months to 21 years old
- Solid tumor or brain tumor that has progressed or spread
- Failed standard treatment
- RET gene alteration
MEKPEM: A Phase I/II trial of MK-3475 (pembrolizumab) in children’s solid tumors and lymphomas
Diseases Treated:
Advanced melanoma or PD-L1 positive advanced relapsed or refractory solid tumor or lymphoma or high-grade glioma
Eligibility:
- Between 6 months and 18 years old with diagnosis of MSI-H solid tumor OR
- Between 12 years and 18 years old with diagnosis of melanoma OR
- Between 3 and 18 years old with relapsed or refractory classical Hodgkin lymphoma OR
- Between 12 and 18 years old with a diagnosis of Stage IIB, IIC, III, or IV melanoma, who had prior surgery to remove the tumor, but no other treatment (including radiation), no metastatic disease, and who have completely recovered.
- Negative pregnancy test 72 hours prior to medication administration in participants of child-bearing potential
- Appropriate liver and kidney functions
PBTC45: MK-3475 in Treating Children with Recurrent, Progressive or Refractory HGGs, DIPGs and Hypermutated Brain Tumors
Diseases Treated:
Recurrent, progressive, or refractory high-grade gliomas
Eligibility:
- Participant has recurrent, progressive or refractory non-brainstem high-grade glioma or diffuse intrinsic pontine glioma (DIPG)
- Participant is 1 to 18 years of age
- Participant has bi-measurable disease on MRI
- Participant has received prior radiation therapy and/or chemotherapy and has not received myelosuppressive anticancer chemotherapy for at least three (3) weeks
PBTC48: Study of the Optune Device in Children with Certain High-Grade Glioma and Ependymoma Brain Tumors
Diseases Treated:
High-grade glioma (HGG), ependymoma
Eligibility:
- Between 5 and 21 years old
- Diagnosis of supratentorial high-grade glioma (HGG) or supratentorial ependymoma that is recurrent, progressive or refractory
- Head circumference of at least 44 cm
- Failed standard therapy with no other available treatment options
- Recovered from prior chemotherapy, immunotherapy or radiotherapy
- Willing and able to use the device at least 18 hours a day for at least 23 days and keep head shaved throughout treatment
PBTC49: Study of Savolitinib in Recurrent, Progressive or Refractory Medulloblastoma, HGG or DIPG
Diseases Treated:
Diffuse intrinsic pontine glioma (DIPG)
Eligibility:
- Recurrent, refractory or progressive medulloblastoma, high-grade glioma (HGG) or diffuse intrinsic pontine glioma (DIPG)
- Evidence of genetic activation of the MET pathway (expansion co-hort)
- At least 5 years old and 21 years old or younger
PNOC013: Study of REGN2810 Immunotherapy in Children with Relapsed or Refractory Solid or CNS Tumors and Study of REGN2810 combined with radiation in Children with Newly Diagnosed or Recurrent Glioma
Diseases Treated:
Diffuse Intrinsic Pontine Glioma, Glioma, CNS Tumor, Solid Tumor
Eligibility:
- Diagnosed with one of the following:
- Recurrent or refractory solid tumor or central nervous system (CNS) tumor
- Diffuse Intrinsic Pontine Glioma (DIPG)
- Newly diagnosed or recurrent high-grade glioma
- Younger than 18 years old (Phase I) or between 3 and 25 years old (Efficacy Phase)